In NSCLC with EGFR mutation, the activation of several signal pathways, such as MAPK/ERK and PI3K/AKT, is considered to be one of the major mechanisms responsible for acquiring drug resistance against EGFR TKIs [97]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.